VTYX

MKT CAP:$1B

Ventyx Biosciences, Inc.

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$14.00+$5.60 (+66.67%)

Mar 6, 2026

Company Details

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 in...

CEO

Sheila K. Gujrathi

IPO Date

Oct 21, 2021

Website

www.ventyxbio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$107M

EPS (Diluted)

-$1.50

Free Cash Flow

-$88M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q3 2025

Nov 6, 2025

$0EPS -$0.32

Q2 2025

Aug 7, 2025

$0EPS -$0.38

Q1 2025

May 8, 2025

$0EPS -$0.39

FY 2024

Feb 27, 2025

$0EPS -$1.97

Q4 2024

Feb 27, 2025

$0EPS -$0.41

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	$0	-$18M
Q1 22	$0	$0	-$23M
Q2 22	$0	$0	-$20M
Q3 22	$0	$0	-$31M
Q4 22	$0	$0	-$39M
Q1 23	$0	$0	-$43M
Q2 23	$0	$0	-$57M
Q3 23	$0	$0	-$58M
Q4 23	$0	$0	-$50M
Q1 24	$0	-$408.0K	-$42M
Q2 24	$0	-$316.0K	-$36M
Q3 24	$0	$0	-$39M
Q4 24	$0	$0	-$32M
Q1 25	$0	$0	-$30M
Q2 25	$0	$0	-$29M
Q3 25	$0	$0	-$25M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$15M	-$15M
Q1 22	-$13M	-$13M
Q2 22	-$15M	-$15M
Q3 22	-$24M	-$24M
Q4 22	-$47M	-$47M
Q1 23	-$31M	-$31M
Q2 23	-$49M	-$49M
Q3 23	-$35M	-$35M
Q4 23	-$52M	-$52M
Q1 24	-$48M	-$48M
Q2 24	-$25M	-$25M
Q3 24	-$35M	-$35M
Q4 24	-$23M	-$23M
Q1 25	-$26M	-$26M
Q2 25	-$21M	-$21M
Q3 25	-$18M	-$18M

Capital Expenditures

Quarter	CapEx
Q4 21	$48.0K
Q1 22	$38.0K
Q2 22	$28.0K
Q3 22	$97.0K
Q4 22	$112.0K
Q1 23	$60.0K
Q2 23	$195.0K
Q3 23	$48.0K
Q4 23	$211.0K
Q1 24	$175.0K
Q2 24	$60.0K
Q3 24	$0
Q4 24	$6.0K
Q1 25	$16.0K
Q2 25	$42.0K
Q3 25	$50.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+1137.9%
Q1 22	—	-10.3%
Q2 22	—	+82.4%
Q3 22	—	+145.7%
Q4 22	—	+116.4%
Q1 23	—	+87.1%
Q2 23	—	+180.2%
Q3 23	—	+84.4%
Q4 23	—	+30.5%
Q1 24	—	-1.8%
Q2 24	—	-37.5%
Q3 24	—	-33.5%
Q4 24	—	-35.6%
Q1 25	—	-27.9%
Q2 25	—	-17.9%
Q3 25	—	-35.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$1M	—
Q1 22	$3M	—
Q2 22	$4M	—
Q3 22	$4M	—
Q4 22	$5M	—
Q1 23	$7M	—
Q2 23	$8M	—
Q3 23	$8M	—
Q4 23	$6M	—
Q1 24	$7M	—
Q2 24	$6M	—
Q3 24	$5M	—
Q4 24	$5M	—
Q1 25	$5M	—
Q2 25	$5M	—
Q3 25	$5M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 21	$14M	$4M
Q1 22	$17M	$5M
Q2 22	$15M	$6M
Q3 22	$25M	$6M
Q4 22	$30M	$8M
Q1 23	$35M	$7M
Q2 23	$49M	$9M
Q3 23	$50M	$8M
Q4 23	$42M	$8M
Q1 24	$34M	$8M
Q2 24	$28M	$8M
Q3 24	$31M	$8M
Q4 24	$25M	$8M
Q1 25	$23M	$7M
Q2 25	$22M	$7M
Q3 25	$18M	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$71M	$188M	$259M
Q1 22	$42M	$213M	$254M
Q2 22	$45M	$205M	$250M
Q3 22	$263M	$149M	$412M
Q4 22	$65M	$253M	$318M
Q1 23	$64M	$313M	$377M
Q2 23	$52M	$281M	$332M
Q3 23	$57M	$244M	$301M
Q4 23	$52M	$201M	$252M
Q1 24	$142M	$161M	$303M
Q2 24	$41M	$199M	$239M
Q3 24	$62M	$213M	$275M
Q4 24	$27M	$190M	$217M
Q1 25	$28M	$201M	$229M
Q2 25	$32M	$177M	$209M
Q3 25	$32M	$161M	$193M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	47M	0.0%	-3.1%
Q1 22	51M	+7.0%	+3.7%
Q2 22	51M	+0.5%	+4.2%
Q3 22	52M	+1.6%	+9.3%
Q4 22	57M	+9.8%	+20.0%
Q1 23	58M	+1.6%	+13.9%
Q2 23	59M	+1.6%	+15.2%
Q3 23	59M	+0.6%	+14.0%
Q4 23	59M	+0.3%	+4.1%
Q1 24	62M	+4.7%	+7.3%
Q2 24	71M	+14.1%	+20.5%
Q3 24	71M	+0.2%	+20.0%
Q4 24	71M	+0.2%	+19.9%
Q1 25	71M	+0.5%	+15.0%
Q2 25	71M	+0.1%	+0.9%
Q3 25	71M	+0.1%	+0.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$0	27
Q1 22	$0	27
Q2 22	$0	27
Q3 22	$0	27
Q4 22	$0	58
Q1 23	$0	58
Q2 23	$0	58
Q3 23	$0	58
Q4 23	$0	79
Q1 24	$0	79
Q2 24	$0	79
Q3 24	$0	79
Q4 24	$0	79
Q1 25	$0	79
Q2 25	$0	79
Q3 25	$0	79

Revenue / Employee